The Revised Agenda, the revised proxy form and all other meeting documentation are now available on the Company's website (www.benevolent.com/investors/general-meetings/) and at the Company's registered office.
The shareholders entitled to participate and vote at the 2024 AGM will be those who are shareholders on the record date of
Contact:
Email: fleur.wood@benevolent.ai
Tel: +44(0) 203 781 9360
Email: cosec@benevolent.ai
Tel: +44(0) 203 781 9360
About BenevolentAI
At BenevolentAI (AMS: BAI), we serve patients by leveraging our proprietary and validated Benevolent PlatformTM that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery. The Company's business model presents multiple routes for value creation including discovery collaborations with pharma companies like
(C) 2024 Electronic News Publishing, source